For Sale Unique And New Medicinal Product

Intelligent Business Transfer are delighted to bring to the market an exceptional medicine which offers a lucrative opportunity for a new buyer looking to acquire a high-class product.

This is extraordinary platform for an existing pharmaceutical company or blue-chip company with the resources to distribute this medicine on an international scale. The product has been developed and tested and is guaranteed to benefit the new buyer and help them generate a high yearly revenue.

Ideal for a business owner already working within the industry, there is vast opportunity for expansion through acquisition. Further initiatives could be implemented by a new owner to grow its market. Actively approaching more private clients and explaining the drug in detail would help to reach out to those who need what the tablet has to offer.

Launching an online presence through a professional website and complimentary social media platforms would help to further expand the overseas client base, particularly in countries where the product hasn’t been marketed in yet. This could also be achieved by setting up an additional office in a country where the demand of viral infection medicine exceeds supply.

Considering that the components of new drug are available at low cost, and based on data available from USA market; we suggest that pricing of the prescription drug is about £20 for low strength and £30 for high strength packs covering a course of 5 days.

The current owner expects the costs of the drug to be as follows: ‘£1.25’ to produce, £0.20 to advertise, £0.10 for insurance and £0.20 for distribution. At ‘cost of £2’ per pack; you may aim to sell it at a price of £17 with recommended retail price of ‘£20 per pack. Using the USA figures of 84 million prescriptions per year and profit of £15 per pack, there are estimated calculations of a minimum net profit of £1260 million per year in USA only.

The current owners, for an OTC drug, suggest a retail price of £10 for low strength and £15 for a high strength pack. Using the USA figures of 500 million episodes of VRTIs per year, at least half of those affected will seek drug treatment. Thus, we calculate a total income of at least £2500 million per year and a minimum profit of £2000 million per year for the USA market only.

Intelligent Business Transfer are searching for a suitable buyer.